Human granulocytic ehrlichiosis

Clinical Infectious Diseases

Volumn 31, Issue 2, 2000, Pages 554-560

  Bakken, Johan S ^a   Dumler, J Stephen ^b  

^a Duluth Clinic   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHLORAMPHENICOL; DNA; DOXYCYCLINE; INSECTICIDE; RIFAMPICIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ARTICLE; BLOOD CELL COUNT; BLOOD SMEAR; EHRLICHIOSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IXODES; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY;

ANIMALS; EHRLICHIA; EHRLICHIOSIS; GRANULOCYTES; HUMANS;

EID: 0034457171     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313948     Document Type: Article

References (82)

1. Human granulocytic ehrlichiosis in the United States: A new species emerging?
2. Identification of granulocytotropic Ehrlichia species as the etiologic agent of human disease
3. The tribe ehrlichia and ehrlichial diseases
4. Emergence of ehrlichioses as human health problems
5. Ehrlichial diseases of humans: Emerging tick-borne infections
6. Human ehrlichioses. Newly recognized infections transmitted by ticks
7. Fatal pancarditis associated with human granulocytic ehrlichiosis in a 44-year-old man
8. Brachial plexopathy associated with human granulocytic ehrlichiosis
9. Demyelinating polyneuropathy associated with human granulocytic ehrlichiosis
10. Ehrlichia equi infection associated with rhabdomyolysis
11. Ixodes dammini as a potential vector of human granulocytic ehrlichiosis
12. Transmission of human granulocytic ehrlichiosis
13. Human granulocytic ehrlichiosis: A case series from a single medical center in New York State
14. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle
15. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease
16. Transmission of the agent of human granulocytic ehrlichiosis by host seeking Ixodes scapularis in southern New York State
17. Deer ticks (Ixodes scapularis) and the agents of Lyme disease and human granulocytic ehrlichiosis in a New York City park
18. Hemocytic Rickettsia-like organisms in ticks: Serologic reactivity with antisera to Ehrlichia and detection of DNA of agent of human granulocytic ehrlichiosis by PCR
19. Distribution of Ixodes ricinus-like ticks of eastern North America
20. Ixodes pacificus as a vector of Ehrlichia equi
21. Ehrlichia phagocytophila genogroup rickettsia in ixodid ticks from California collected in 1995 and 1996
22. Identity of ehrlichial DNA sequences derived from Ixodes ricinus ticks with those obtained from patients with human granulocytic ehrlichiosis in Slovenia
23. The human granulocytic ehrlichiosis agent in Swedish ticks
24. Does human ehrlichiosis exist in Sweden?
25. Natural infection of small mammal species in Minnesota with the agent of human granulocytic ehrlichiosis
26. Serologic evidence of infection with Ehrlichia spp. in wild rodents in the United States
27. Infection with the agents of human granulocytic ehrlichiosis, Lyme disease, and babesiosis in wild white-footed mice in Connecticut
28. Reservoir competence of white tailed deer for the agent of human granulocytic ehrlichiosis
29. Prevalence of granulocytic Ehrlichia infection among white-tailed deer in Wisconsin
30. Serologic evidence of a natural infection of white-tailed deer with the agent of human granulocytic ehrlichiosis in Wisconsin and Maryland
31. The ecology of Lyme disease risk
32. Spatial analysis of the distribution of Lyme disease in Wisconsin
33. Lyme disease: United States, 1995
34. The human ehrlichioses in the United States
35. Human granulocytic ehrlichiosis: Report of a case in northern California
36. Human granulocytic ehrlichiosis in northern California: Two case descriptions with genetic analysis of the ehrlichiae
37. Human disease in Europe caused by a granulocytic Ehrlichia species
38. Human granulocytic ehrlichiosis in western Europe
39. Variable presentation and course in human granulocytic ehrlichiosis: Twelve case reports of the new tick-borne zoonosis
40. Human monocytic and granulocytic ehrlichioses
41. Clinical and laboratory characteristics of human granulocytic ehrlichiosis
42. Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States
43. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin
44. Serological evidence of human granulocytic ehrlichiosis an Norway
45. A population-based seroepidemiologic study of human granulocytic ehrlichiosis and Lyme borreliosis on the west coast of Sweden
46. Serological evidence of Ehrlichia infection in Swedish Lyme borreliosis patients
47. Human granulocytic ehrlichiosis in Europe
48. Human ehrlichiosis in the UK
49. Ehrlichia infection in Italy
50. Human granulocytic ehrlichiosis in Bulgaria
51. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis
52. Human granulocytic ehrlichiosis in New York
53. Environmental risk and prevention of Lyme disease
54. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis
55. Serial measurements of hematological counts during the active phase of human granulocytic ehrlichiosis
56. Influence of occupation, pre-existing illnesses, and chronic medication use on the severity of illness of human granulocytic ehrlichiosis
57. Sequential changes in blood counts during the natural course of human granulocytic ehrlichiosis
58. Clinical and laboratory evolution of a culture confirmed case of human granulocytic ehrlichiosis
59. Direct cultivation of the causative agent of human granulocytic ehrlichiosis
60. Consensus workshop on diagnosis of human ehrlichioses
61. Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic ehrlichia
62. An indirect immunofluorescence assay using a cell-culture derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis
63. The early humoral response in human granulocytic ehrlichiosis
64. Human exposure to granulocytic ehrlichia and other tick-borne agents in Connecticut
65. Reactivity of human sera to different strains of granulocytic ehrlichiae in immunodiagnostic assays
66. Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates
67. Serodiagnosis of human granulocytic ehrlichiosis by a recombinant HGE-44-based enzyme-linked immunosorbent assay
68. Inter- and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis agent strains for serodiagnosis of HGE by the immunofluorescent antibody test
69. Serologic testing for human granulocytic ehrlichiosis at a natural referral center
70. Evaluation of improved PCR diagnostic assay for human granulocytic ehrlichiosis
71. PCR amplification and comparison of nucleotide sequences from the groESL heat shock operon of Ehrlichia species
72. Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using epankl genes of Ehrlichia phagocytophila-group ehrlichiae
73. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: Promising activity of quinolones and rifamycins
74. Ehrlichia species
75. Ehrlichiosis
76. Should tetracycline therapy be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age?
77. Perinatal transmission of the agent of human granulocytic ehrlichiosis
78. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin
79. Duration of tick attachment required for transmission of granulocytic ehrlichiosis
80. Duration of IFA serologic response in humans infected with the agent of human granulocytic ehrlichiosis
81. Serology of culture confirmed cases of human granulocytic ehrlichiosis
82. Reinfection with the agent of human granulocytic ehrlichiosis